ECM
BOLD

Endurant Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Endurant Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,235
Closed -$819K – 102
2017
Q3 		$819K Buy
29,235
+35
+0.1% +$760 0.25% 72
2017
Q2 		$559K Buy
+29,200
New +$466K 0.16% 83

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Endurant Capital Management's BOLD Position: Q4 2017 in Review

Endurant Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2017, closing a stake of 29,235 shares — an estimated $819K sold.

Endurant Capital Management first reported a position in BOLD in Q2 2017 and held it in 2 quarters. The position peaked at $819K in Q3 2017. 89 funds tracked by Wall St. Rank hold BOLD as of Q4 2017.

  • Endurant Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2017 after selling out during the quarter.
  • Endurant Capital Management sold 29,235 Audentes Therapeutics, Inc shares in Q4 2017, an estimated $819K.
  • Endurant Capital Management first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 2 quarters.
  • Endurant Capital Management's Audentes Therapeutics, Inc position peaked at $819K in Q3 2017.
  • 89 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.